Business Wire

  1. insitro Extends Research Collaboration With Bristol Myers Squibb Leveraging insitro's ChemML Discovery Platform 10/14/2025

    insitro, a pioneer in machine learning–driven drug discovery and development, and Bristol Myers Squibb, today announced the next phase of their collaboration to discover new molecules with potential as new treatments for amyotrophic lateral sclerosis (ALS).

  2. BenchSci Announces Three-Year License Agreement With Sanofi To Access And Use BenchSci's ASCEND Platform 10/8/2025

    BenchSci, a world leader in AI solutions for preclinical research and drug discovery, today announced a three-year agreement with Sanofi to deploy and use BenchSci’s ASCEND platform across Sanofi’s global preclinical research organization.

  3. Algen Biotechnologies Announces Multi-Target Partnership To Advance AI-Powered Drug Discovery In Immunology With AstraZeneca 10/6/2025

    Algen Biotechnologies, a biotechnology company pioneering next-generation therapies using advanced CRISPR gene modulation and AI-driven drug discovery, today announced a multi-target partnership with AstraZeneca to accelerate the discovery of novel therapeutic targets in immunology.

  4. QuantHealth Secures Strategic Investment From Sanofi Ventures To Accelerate AI-Driven Clinical Trials 10/1/2025

    QuantHealth, a pioneer in AI-driven clinical trial simulation, announced a strategic investment from Sanofi Ventures, the venture capital arm of global healthcare leader Sanofi. The investment will accelerate QuantHealth’s efforts to bring scalable, patient-level simulations and digital twin technologies to the forefront of drug development, bringing its total funds raised to $30M.

  5. Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation By U.S. FDA For The Treatment Of Alzheimer's Disease 10/1/2025

    Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BMS-986446, a potential best-in-class anti-microtubule binding region-tau (anti-MTBR-tau) antibody currently in Phase 2 development for the treatment of early Alzheimer’s disease.

  6. Merck And Siemens Deepen Strategic Partnership To Accelerate AI And Data-Driven Drug Discovery And Development 9/23/2025

    Merck, a leading science and technology company, and Siemens, a leading technology company, signed a new Memorandum of Understanding (MoU), extending their strategic partnership to accelerate digital transformation in the life science industry.

  7. Variational AI Enters Collaboration With Merck To Apply Generative AI To Drug Discovery 9/23/2025

    Variational AI, Inc., a generative AI drug discovery company, today announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply Variational AI’s Enki platform to design and optimize novel small molecule candidates against two undisclosed targets.

  8. xFOREST Therapeutics And Axcelead DDP Launch Joint Research Initiative On RNA Structure-Targeted Small Molecule Drug Discovery 9/19/2025

    xFOREST Therapeutics Co., Ltd. (“xFOREST”) and Axcelead Drug Discovery Partners, Inc. (“Axcelead DDP”) today announced the launch of a joint research collaboration aimed at developing RNA structure-targeted small molecule therapeutics for multiple diseases.

  9. Rubedo Life Sciences Announces U.S. FDA Clearance Of IND For Selective GPX4 Modulating Lead Drug Candidate RLS-1496 For Actinic Keratosis, Expands Clinical Advisory Board 9/17/2025

    Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 1b/2a study with lead drug candidate RLS-1496 in patients with actinic keratosis.

  10. FDA Files Corcept's New Drug Application For Relacorilant As A Treatment For Patients With Platinum-Resistant Ovarian Cancer 9/10/2025

    Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the U.S. Food and Drug Administration (FDA) has accepted Corcept’s New Drug Application (NDA) for relacorilant as a treatment for patients with platinum-resistant ovarian cancer